A database study analyzing more than 150,000 tumor samples identified 11 shared T-cell receptor (TCR) families, including nine previously unknown. The authors frame these shared repertoires as potential starting points for future TCR-based or engineered immunotherapies. For biotech, shared TCR families are valuable because they can imply convergent immune recognition that may be transferable across patients, potentially improving manufacturability and reducing personalization complexity. However, clinical translation will depend on whether the identified receptors correspond to meaningful tumor antigens and can drive effective cytotoxicity. The immediate relevance is for target discovery pipelines: selecting TCR candidates with strong antigen linkage and consistent functional behavior across tumor types and HLA contexts.